[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman; John Violet; Rodney J. Hicks; Justin Ferdinandus; Sue Ping Thang; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Declan G. Murphy; Peter Eu; Price Jackson; Mark Scalzo; Scott Williams; Shahneen Sandhu

doi:10.1016/s1470-2045(18)30198-0

Keywords

MedicineProstate cancerTaxaneClinical endpointOncologyInternal medicineProgressive diseaseResponse Evaluation Criteria in Solid TumorsProstateCancerClinical trialChemotherapyUrologyBreast cancer

Affiliated Institutions

Related Publications

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor , Johann S. de Bono , Kim N. +17 more

BACKGROUND: Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic ca...

2021 New England Journal of Medicine 2181 citations

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman , Nathan Lawrentschuk , Roslyn J. Francis +23 more

Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging...

2020 The Lancet 1768 citations

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N. , Neeraj Agarwal , Anders Bjartell +17 more

In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer wit...

2019 New England Journal of Medicine 1384 citations

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Anthony W. Tolcher , Steven Sugarman , Karen A. Gelmon +7 more

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is direc...

1999 Journal of Clinical Oncology 266 citations

Genomic correlates of clinical outcome in advanced prostate cancer

Wassim Abida , Joanna Cyrta , Glenn Heller +40 more

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of...

2019 Proceedings of the National Academy o... 1301 citations

Publication Info

Year: 2018
Type: article
Volume: 19
Issue: 6
Pages: 825-833
Citations: 1085
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1085

OpenAlex

Cite This

APA Style

                            
                                
                                    Michael S. Hofman, 
                                
                                    John Violet, 
                                
                                    Rodney J. Hicks
                                
                                et al.
                            
                            (2018). 
                            [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. 
                            The Lancet Oncology
                            , 19
                            (6)
                            , 825-833.
                            https://doi.org/10.1016/s1470-2045(18)30198-0
                        

Identifiers

DOI: 10.1016/s1470-2045(18)30198-0